Q3 2024
Released Nov 13, 2024, after the close
10-Q filed Nov 14, 2024, 45 days after period end · 0001493152-24-045793
Q3 2024 · 10-Q
Revenue$3.52M$3.52M −6.0% vs Q3 2023+8.2% vs Q2 2024
Net Income$183.00K$183.00K N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted$0.02$0.02 N/M vs Q3 2023N/M vs Q2 2024
Gross Profit$2,149,000−2.1%
Operating Income$206,000N/M
Operating Cash Flowderived-$623,000N/M
Free Cash Flowderived-$623,000—
Margins · derived
Gross margin61.1%+2.5 pt vs Q3 2023
Operating margin5.9%+11.3 pt vs Q3 2023
Net margin5.2%+10.1 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $3.52M | $3.74M | $2.41M | $2.58M |
| Net Income | $183.00K | -$182.00K | -$3.23M | -$1.22M |
| EPS Diluted | $0.02 | -$0.02 | -$0.31 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR